Third Circuit Revives FCA Action over Plavix Marketing
- September 04, 2020
The Third Circuit reversed September 1 the dismissal of a whistleblower action against Sanofi-Aventis and Bristol Myer’s Squibb alleging they improperly promoted the blood thinner drug Plavix.
ARTICLE TAGS
You must be logged in to access this content.